- Home
- DMLP vs MNMD Comparison
DMLP vs MNMD Comparison
Compare DMLP & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- MNMD
- Stock Information
- Founded
- DMLP 2003
- MNMD 2019
- Country
- DMLP United States
- MNMD United States
- Employees
- DMLP N/A
- MNMD N/A
- Industry
- DMLP Oil & Gas Production
- MNMD Pharmaceuticals and Biotechnology
- Sector
- DMLP Energy
- MNMD Health Care
- Exchange
- DMLP Nasdaq
- MNMD Nasdaq
- Market Cap
- DMLP 1.1B
- MNMD 960.2M
- IPO Year
- DMLP N/A
- MNMD N/A
- Fundamental
- Price
- DMLP $22.88
- MNMD $12.51
- Analyst Decision
- DMLP
- MNMD Strong Buy
- Analyst Count
- DMLP 0
- MNMD 9
- Target Price
- DMLP N/A
- MNMD $25.78
- AVG Volume (30 Days)
- DMLP 145.5K
- MNMD 2.2M
- Earning Date
- DMLP 11-06-2025
- MNMD 11-06-2025
- Dividend Yield
- DMLP 14.06%
- MNMD N/A
- EPS Growth
- DMLP N/A
- MNMD N/A
- EPS
- DMLP 1.13
- MNMD N/A
- Revenue
- DMLP $143,803,000.00
- MNMD N/A
- Revenue This Year
- DMLP N/A
- MNMD N/A
- Revenue Next Year
- DMLP N/A
- MNMD N/A
- P/E Ratio
- DMLP $20.16
- MNMD N/A
- Revenue Growth
- DMLP N/A
- MNMD N/A
- 52 Week Low
- DMLP $22.56
- MNMD $4.70
- 52 Week High
- DMLP $34.88
- MNMD $14.43
- Technical
- Relative Strength Index (RSI)
- DMLP 34.80
- MNMD 53.19
- Support Level
- DMLP $22.55
- MNMD $10.61
- Resistance Level
- DMLP $23.87
- MNMD $12.89
- Average True Range (ATR)
- DMLP 0.60
- MNMD 0.92
- MACD
- DMLP -0.18
- MNMD -0.18
- Stochastic Oscillator
- DMLP 13.19
- MNMD 49.08
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).